Syntopia combines advanced 3D cell culture, organoids, and innovative microfluidics to help to biotech and pharmaceutical industries generate high-quality biological data at scale - accelerating research and reducing clinical failure rates
In drug discovery, over 90% of drug candidates fail in clinical trials.
Traditional models - 2D cell cultures and animal testing - poorly predict human biology, driving huge costs and delays for biotech and pharma
Syntopia brings together physiologically relevant 3D biology and a breakthrough microfluidic platform to generate better preclinical data, cheaper and faster
3D cell culture & organoids
Scaffold-based tissue models with long-term viability and functional assays
Innovative microfluidics
Pump-free, open format, fully compatible with robotics - enabling high-throughput experiments and large-scale data generation without specialized instruments
Multi-modal readouts
Immunofluorescence imaging, secretome chemical analysis, and RNA sequencing after treatment - delivering a comprehensive view of cell responses
Datasets of unmatched quality for AI-driven biomarker detection, drug response prediction, and virtual cohort creation
Our solution is modular - we can adapt the device design and assay configuration to meet specific application needs.
Current focus on three applications:
Patient-derived tumoroids / organoids with immune cell co-culture
Enables functional studies: migration, cytotoxicity, CAR-T/CAR-NK screening
Primary Human Hepatocyte model, viable > 21 days
Enables robust datasets for in silico toxicity prediction
Brain microenvironment organoids integrating microglia
Supports personalized medicine and early-stage neurotoxicology
Join us us in the Breakthrough Zone in Liverpool (21–22 Oct 2025)
French innovation hub that connects academia, hospitals, startups, and industry to accelerate cancer research and therapeutic development
France’s national deep-tech innovation contest supporting early-stage startups with funding and visibility.
€150k EU funding to validate the commercial and societal potential of our research results.